Search
Kazia Therapeutics Ltd
KZIAAdd to Watchlist
13.250USD
-0.140-1.05%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
142.20MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
4
analysts
Buy
Current Rating
26.250
Target Price
+81.54%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Kazia Therapeutics Ltd
KZIA
4
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Kazia Therapeutics Ltd's price target?
Analysts forecast that Kazia Therapeutics Ltd's price target is USD 16.50, with the highest forecast at USD 20.00 and the lowest forecast at USD 13.00.
How have Kazia Therapeutics LtdKZIA's recent earnings per share performed?
The market expectation was USD -40.60, while Kazia Therapeutics LtdKZIA's earnings per share (EPS) for the previous quarter was USD -12.22. EPS for the next quarter is expected at USD -0.22.
What is the analyst rating for Kazia Therapeutics Ltd?
Based on the ratings of Kazia Therapeutics Ltd's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.